Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction

Leuk Res. 2019 Aug:83:106174. doi: 10.1016/j.leukres.2019.106174. Epub 2019 Jun 21.

Authors

Bryan C Hambley¹, Kelly J Norsworthy¹, Jagar Jasem¹, Jacquelyn W Zimmerman¹, Eugene Shenderov¹, Jonathan A Webster¹, Margaret M Showel¹, Lukasz P Gondek¹, William B Dalton¹, Gabrielle Prince¹, Douglas E Gladstone¹, Michael B Streiff², Keith W Pratz³, Ivana Gojo³, Gabriel Ghiaur³, Mark J Levis³, B Douglas Smith³, Amy E DeZern⁴

Affiliations

¹ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.
² Department of Hematology, Johns Hopkins Hospital, Baltimore, MD, United States.
³ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD United States.
⁴ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD United States. Electronic address: adezern1@jhmi.edu.

PMID: 31255938
DOI: 10.1016/j.leukres.2019.106174

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Aged
Female
Fibrinogen / metabolism*
Hemorrhage* / blood
Hemorrhage* / drug therapy
Hemorrhage* / mortality
Heparin / administration & dosage*
Humans
Leukemia, Promyelocytic, Acute* / blood
Leukemia, Promyelocytic, Acute* / drug therapy
Leukemia, Promyelocytic, Acute* / mortality
Male
Middle Aged
Retrospective Studies
Risk Factors

Substances

Fibrinogen
Heparin